Related Experiment Videos
Cefiderocol non-susceptibility among carbapenem-resistant Enterobacterales: Data from the 2024 Antimicrobial Testing
Po-Wei Chiu1, Jiun-Ling Wang2, Shun-Chung Hsueh3
1Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.
Objectives:
To evaluate cefiderocol (FDC) activity against carbapenem-resistant Enterobacterales (CRE) globally, characterize the β-lactamase gene profiles of non-susceptible isolates by metallo-β-lactamase status, and assess alternative agents.
Methods:
Cefiderocol minimum inhibitory concentrations for 1657 CRE isolates from the 2024 Antimicrobial Testing Leadership and Surveillance programme were determined by broth microdilution. Isolates underwent molecular screening for carbapenemase, extended-spectrum β-lactamase, and AmpC genes. Between-group differences were assessed using odds ratios (ORs) with Fisher's exact tests.
Results:
Overall FDC susceptibility rate was 93.1% by Clinical and Laboratory Standards Institute and 80.7% by EUCAST criteria, respectively. Non-susceptibility varied substantially by genus: Escherichia spp. 25.3%, Providencia spp. 14.0%, Enterobacter spp. 12.5%, and Klebsiella spp. 3.5%. FDC non-susceptibility rates revealed further heterogeneity within genera; notably, Enterobacter cloacae (23.1%) and Enterobacter kobei (50.0%) had substantially higher non-susceptibility than Enterobacter hormaechei (7.2%), and Providencia rettgeri (22.2%) exceeded Providencia stuartii (8.0%). Asia had the highest unadjusted non-susceptibility rate (10.5%; OR 4.73, P = 0.002); however, in a multivariable logistic regression adjusting for genus, age, and specimen source, genus was the dominant independent predictor (Escherichia spp. adjusted OR 8.21, 95% confidence interval 4.75-14.17), and the Asia effect was attenuated to a non-significant trend (adjusted OR 3.99, 0.93-17.14, P = 0.063). Among 115 non-susceptible isolates, 51 (44.3%) were metallo-β-lactamase-positive, predominantly blaNDM (94.1%), with high extended-spectrum β-lactamase co-carriage (blaCTX-M 74.5%), while 50 (43.5%) harboured no identifiable carbapenemase gene.
Conclusions:
FDC remains active against most CRE globally, although non-susceptibility varies by genus, species and region. Notably, nearly half of non-susceptible isolates lacked detectable carbapenemase genes.
Related Concept Videos
Clinical Significance of Antibiotic Resistance
Development of Antibiotic Resistance
Antibiotic Selection